What records are connected here?
- Evidence lanes
- 3
- Source years
- 24
- Drugs@FDA applications
- 8
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsHormones · Brain, nerves and sleep
Oxytocin is a nine-amino-acid peptide hormone found in the pituitary gland. A synthetic version is the active ingredient in Pitocin.1,2 Its U.S. label covers starting or strengthening labor contractions when there is a medical reason, and controlling bleeding after birth. The label states that it is not indicated for elective induction of labor.1 In a randomized trial of 29,645 participants published in 2018, oxytocin and heat-stable carbetocin, a related drug, prevented heavy bleeding after vaginal birth about equally often.3
| What it is | A synthetic version of oxytocin, a nine-amino-acid hormone found in the pituitary gland, according to the Pitocin label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Pitocin, NDA 018261, with an original approval date of November 19, 1980. The label’s boxed warning states that it is not indicated for elective induction of labor.1,2 |
| Human evidence | Decades of clinical use described in the label, which does not report its own trials, and large randomized trials published in journals, including one of 29,645 participants.1,3 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Oxytocin is a peptide hormone of nine amino acids found in pituitary extracts from mammals. The version in Pitocin is made synthetically, which the label says avoids possible contamination with vasopressin.1
In the United States it is the active ingredient of Pitocin, approved under NDA 018261, according to Drugs@FDA.2
The label states that oxytocin promotes contractions of the uterus by raising calcium inside its muscle cells, acting on oxytocin receptors whose number rises greatly during pregnancy.1
The label also states that oxytocin has some antidiuretic and blood-pressure effects, because it differs from vasopressin in only two of its amino acids.1
The Pitocin label describes how oxytocin acts and its risks, but does not report clinical trials of its own.1
ClinicalTrials.gov lists completed Phase 4 trials of oxytocin in bleeding after birth caused by a slack uterus (NCT00790062) and in strengthening labor (NCT00906347).4,5
Registered trials also study oxytocin outside its labeled uses. ClinicalTrials.gov lists completed Phase 2 studies in postpartum depression and anxiety (NCT02505984) and in autism spectrum disorder (NCT02918864); the registry records cited here do not report their findings.6,7
CHAMPION, a randomized, double-blind trial of 29,645 participants in 10 countries published in 2018, compared oxytocin with heat-stable carbetocin given right after vaginal birth. Blood loss of at least half a litre, or the need for more drugs to contract the uterus, occurred in 14.4% of those given oxytocin and 14.5% of those given carbetocin.3
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Pitocin, application NDA 018261, with an original approval date of November 19, 1980.2
The Pitocin label cited here (DailyMed SPL version 15, published May 21, 2026) states that it is indicated to start or improve contractions when there is a medical reason to deliver, to reinforce labor in selected cases, as an added treatment in incomplete or inevitable abortion, and after birth to control bleeding.1
The label carries a boxed warning, headed “Important notice”, stating that Pitocin is not indicated for elective induction of labor because the available data are inadequate to weigh its benefits and risks for that use.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Oxytocin is not among them.8,9
Whether its benefits outweigh its risks for elective induction of labor, which the label states the available data are inadequate to judge.1
Whether oxytocin helps in conditions outside pregnancy and birth, such as postpartum depression or autism: registered trials have studied these, but the registry records cited here do not report results.6,7
Whether carbetocin prevents the heaviest bleeding as well as oxytocin: in CHAMPION, the result for blood loss of at least one litre did not show that, partly because such bleeding was rare.3
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Oxytocin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Oxytocin are a bounded selection, not every registration or paper about Oxytocin. For the years before Oxytocin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Oxytocin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Oxytocin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Pitocin for labor and bleeding after birth. The label does not report its own trials. A randomized trial of 29,645 participants found oxytocin and heat-stable carbetocin similar for preventing bleeding after vaginal birth. The label states that Pitocin is not indicated for elective induction of labor.↗↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Pitocin for labor and bleeding after birth. The label does not report its own trials. A randomized trial of 29,645 participants found oxytocin and heat-stable carbetocin similar for preventing bleeding after vaginal birth. The label states that Pitocin is not indicated for elective induction of labor.↗↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 16, 2026
ClinicalTrials.gov record NCT06285396↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06285396↗Source date November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06930391↗Source date November 13, 2026Literature metadata · added November 16, 2026
Oxytocin and social neuroscience - sexually dimorphic OXTR neurons in mouse preoptic area.↗Source date November 12, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
27 of 27 selected trial records include at least one phase value; 27 of 27 include a status value in the retained structured contract.
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00790062 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-04-08, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00906347 at 2026-11-16T00:59:19.138Z. Its registry update date was 2012-11-15, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00919802 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-05-23, and PeptideScanner's reviewed identity mapping was oxytocin.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span April 17, 1980 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06285396 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was oxytocin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06930391 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was oxytocin.↗
Literature metadata
PubMed lists PMID 42191115 in Progress in neurobiology as Journal Article, Review, with publication-date metadata of 2026-05-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42144048 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42002246 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41707759 in Neuroscience and biobehavioral reviews as Journal Article, Systematic Review, with publication-date metadata of 2026-02-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41796877 in Neuroscience and biobehavioral reviews as Journal Article, Review, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41796879 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42093825 in Frontiers in neuroscience as Journal Article, Review, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42766066 in Current diabetes reports as Journal Article, Review, with publication-date metadata of 2026-09-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41619996 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-01-29 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42876328 in Journal of neuroendocrinology as Journal Article, Review, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
The New England Journal of Medicine · Official source · Source checked November 15, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026